As GSK shares fall 5% on Q1 news, is this a buying opportunity?
[ad_1] GSK (LSE: GSK) beat first-quarter earnings expectations Wednesday (29 April), but the shares responded with a 5% drop. Highlights from the update included: Oncology sales up 28%, Shingrix vaccine sales up 20%. Full-year guidance reaffirmed. Over £40bn sales targeted…

